Safety of once-or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study

Simple item page
dc.contributor.authorEmren, SV
dc.contributor.authorZoghi, M
dc.contributor.authorBerilgen, R
dc.contributor.authorÖzdemir, IH
dc.contributor.authorÇelik, O
dc.contributor.authorÇetin, N
dc.contributor.authorEnhos, A
dc.contributor.authorKöseoglu, C
dc.contributor.authorAkyüz, A
dc.contributor.authorDogan, V
dc.contributor.authorLevent, F
dc.contributor.authorDereli, Y
dc.contributor.authorDogan, T
dc.contributor.authorBasaran, Ö
dc.contributor.authorKaraca, I
dc.contributor.authorKaraca, Ö
dc.contributor.authorOtlu, YÖ
dc.contributor.authorÖzmen, Ç
dc.contributor.authorCosar, S
dc.contributor.authorSümerkan, M
dc.contributor.authorGürsul, E
dc.contributor.authorInci, S
dc.contributor.authorOnrat, E
dc.contributor.authorErgene, O
dc.date.accessioned2025-04-10T10:37:28Z
dc.date.available2025-04-10T10:37:28Z
dc.description.abstractOnce-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) may increase patient adherence to treatment but may also be associated with a higher risk of bleeding. In this study, we investigated the adherence to once-or twice-daily dosing of NOACs and the risk of bleeding in nonvalvular atrial fibrillation (NVAF) patients. This multicenter cross-sectional study, conducted between 1 September 2015 and 28 February 2016, included 2214 patients receiving NOACs for at least 3 months, due to NVAF. Patients receiving once-daily or twice-daily NOAC doses were 1: 1 propensity score matched for baseline demographic characteristics and the presence of other diseases. The medication adherence was assessed by the 8-item Morisky Medication Adherence Scale. Risk factors were investigated in relation to minor and major bleeding. The mean age of patients was 71 +/- 10 years, and 53% of the patients were women. The medication adherence was lower in patients receiving twice-daily NOAC doses compared to once-daily-dose group (47% versus 53%, p = 0.001), and there was no difference between the groups in terms of minor (15% versus 16%, p = 0.292) and major bleeding (3% versus 3%, p = 0.796). Independent risk factors for bleeding were non-adherence to medication (OR: 1.62, 95% CI: 1.23-2.14, p = 0.001), presence of 3 or more other diseases (OR: 10.3, 95% CI: 5.3-20.3, p < 0.001), and HAS-BLED (Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile INR, Elderly, Drugs or alcohol) score (OR: 4.84, 95% CI: 4.04-5.8, p < 0.001). In summary, the once-daily dose of NOACs was associated with increased patient adherence to medication, while it was not associated with bleeding complications.
dc.identifier.e-issn1840-4812
dc.identifier.issn1512-8601
dc.identifier.urihttp://hdl.handle.net/20.500.14701/43051
dc.language.isoEnglish
dc.titleSafety of once-or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu